Other-cause mortality in incidental prostate cancer.

Francesco Di BelloAndrea BaudoMario de AngelisLetizia Maria Ippolita JannelloCarolin SiechZhe TianJordan A GoyalClaudia Collà RuvoloGianluigi CalifanoRoberto La RoccaSimone MorraPietro AcquatiFred SaadShahrokh F ShariatLuca CarmignaniOttavio de CobelliAlberto BrigantiFelix K H ChunNicola LongoPierre I Karakiewicz

Published in: The Prostate (2024)

Our results quantified OCM rates, confirming that in not-actively-treated IPCa patients OCM is indeed significantly higher than in their actively-treated counterparts (HR: 1.4). These observations validate the use of no active treatment in IPCa patients, in whom OCM greatly surpasses CSM (20% vs. 5%).

Keyphrases

prostate cancer
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
cardiovascular disease
coronary artery disease
cardiovascular events
patient reported outcomes